Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080450 | 0.87 | HTT (0.41) | AOC3 | |
| SCHEMBL8960092 | 0.86 | SIGMAR1 (0.47) | TAAR1HTR2AKMT2AHSP90AA1SIGMAR1 | |
| SCHEMBL12968214 | 0.85 | SIGMAR1 (0.46) | TAAR1HTR2ASIGMAR1LMNAMAPT | |
| SCHEMBL18425321 | 0.84 | LMNA (0.46) | TAAR1HTR2AKMT2AHSP90AA1SIGMAR1 | |
| SCHEMBL21248200 | 0.83 | SIGMAR1 (0.45) | TAAR1HTR2ASIGMAR1LMNA | |
| SCHEMBL10187975 | 0.82 | TAAR1 (0.52) | TAAR1HTR2AKMT2AHSP90AA1SIGMAR1 | |
| SCHEMBL1624417 | 0.82 | TAAR1 (0.47) | TAAR1HTR2AKMT2AHSP90AA1SIGMAR1 | |
| SCHEMBL4632610 | 0.81 | TSHR (0.40) | AOC3 | |
| SCHEMBL4819998 | 0.80 | LMNA (0.42) | TAAR1HTR2AKMT2AHSP90AA1SIGMAR1 | |
| SCHEMBL9045813 | 0.78 | PTGS1 (0.45) | HTR2ALMNAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4134076-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Redhill Biopharma Ltd. (IL) | 2023-02-15 | — | — | EP | disclosed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| WO-2020012403-A1 | AN IMPROVED PROCESS FOR DIASTER-EOSELECTIVE SYNTHESIS OF VICINAL DIAMINES | Piramal Enterprises Limited (IN) | 2020-01-16 | — | — | WO | disclosed |
| WO-2019183369-A1 | NEURITE OUTGROWTH PROMOTERS AND USES THEREOF | UNIVERSITY OF MIAMI (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20170258805-A1 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-09-14 | — | — | US | disclosed |
| WO-2016109501-A1 | AMIDE COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20140291659-A1 | DIOXAANTHANTHRENE COMPOUND, LAMINATED STRUCTURE AND FORMATION METHOD THEREOF, AND ELECTRONIC DEVICE AND MANUFACTURING METHOD THEREOF | SONY CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2767540-A1 | DIOXAANTHANTHRENE-BASED COMPOUND, LAMINATED STRUCTURE AND MOLDING METHOD THEREOF, AND ELECTRONIC DEVICE AND PRODUCTION METHOD THEREOF | Sony Corporation (JP) | 2014-08-20 | — | — | EP | disclosed |
| CN-103874704-A | Dioxaanthanthrene-based compound, laminated structure and molding method thereof, and electronic device and production method thereof | SONY CORP | 2014-06-18 | — | — | CN | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | TAAR1 1473/4885HTR2A 2326/4885KMT2A 1739/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | TAAR1 3408/4885HTR2A 4479/4885KMT2A 4481/4885 |
| US-20170258805-A1 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE | UGDH, GALE, UGGT1 | TAAR1 2781/4885HTR2A 2679/4885KMT2A 652/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | TAAR1 3408/4885HTR2A 4479/4885KMT2A 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.